What is RS Research?
Founded in 2015 and based in Turkey, RS Research is dedicated to pioneering new therapeutic approaches for cancer patients. The company's core innovation lies in its proprietary nanomedicine drug delivery platforms, designed to enhance the efficacy and targeted delivery of cancer treatments. As a clinical-stage entity, RS Research is focused on translating its scientific advancements into viable medical solutions, positioning itself within the competitive biotechnology landscape.
How much funding has RS Research raised?
RS Research has raised a total of $13.2M across 2 funding rounds:
Private Equity
$1.2M
Series A
$12M
Private Equity (2017): $1.2M with participation from ACT Venture Partners
Series A (2021): $12M led by GEN Ilaç, One life Ventures, and Eczacıbaşı Momentum
Key Investors in RS Research
ACT Venture Partners
ACT Venture Partners is a venture capital firm that invests in early stage deep-tech startups. While ACT is generalist, specific attention were given to startups with AI, IoT, and Big Data/Analytics component. ACT’s investment team is comprised of 4 experienced professionals with diverse and international backgrounds in investment management, entrepreneurship, engineering, and R&D funding and management.
One life Ventures
One life Ventures is a company that operates in the Banking industry. It employs 10to19 people and has 1Mto5M of revenue. The company is headquartered in Mountain View, California.
GEN Ilaç
Undisclosed investor participating in the funding round.
What's next for RS Research?
The recent major strategic investment signals a pivotal growth phase for RS Research, likely enabling the company to accelerate its clinical development pipeline and expand its research and development capabilities. This substantial backing, part of its $13.2M in total capital, suggests confidence from investors in the company's technology and its potential to address unmet needs in oncology. Future endeavors will likely focus on progressing through clinical trials, potentially seeking further strategic partnerships, and solidifying its market position in the advanced therapeutics sector.
See full RS Research company page
